The dipeptidyl peptidase-4 inhibitor may improve the insulin secretion in type 2 diabetes patients just after starting hemodialysis treatment: preliminary study

Preliminary Study ◽

Comparative studies of dipeptidyl peptidase 4 inhibitor vs sulphonylurea among Muslim Type 2 diabetes patients who fast in the month of Ramadan: A systematic review and meta-analysis

Primary Care Diabetes ◽

10.1016/j.pcd.2015.09.001 ◽

2016 ◽

Vol 10 (3) ◽

pp. 210-219 ◽

Cited By ~ 12

Author(s):

Huai Heng Loh ◽

Anne Yee ◽

Huai Seng Loh ◽

Norlela Sukor ◽

Nor Azmi Kamaruddin

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Comparative Studies ◽

Meta Analysis ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Comparison of Safety and Economic Burden of Dipeptidyl Peptidase-4-Inhibitor Versus Sulfonylureas in Type 2 Diabetes Patients Inadequately Controlled with Metformin; A Narrative Review

Indian Journal of Public Health Research & Development ◽

10.37506/ijphrd.v11i7.10232 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Economic Burden ◽

Dipeptidyl Peptidase ◽

Narrative Review ◽

Dipeptidyl Peptidase 4 ◽

Adherence to dipeptidyl peptidase‐4 inhibitor therapy among type 2 diabetes patients with employer‐sponsored health insurance in Japan

Journal of Diabetes Investigation ◽

10.1111/jdi.12474 ◽

2016 ◽

Vol 7 (5) ◽

pp. 737-743 ◽

Cited By ~ 7

Author(s):

Karen Kurtyka ◽

Rie Nishikino ◽

Chie Ito ◽

Kim Brodovicz ◽

Yong Chen ◽

...

Keyword(s):

Type 2 Diabetes ◽

Health Insurance ◽

Dipeptidyl Peptidase ◽

Inhibitor Therapy ◽

Dipeptidyl Peptidase 4 ◽

Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients

Clinical Therapeutics ◽

10.1016/j.clinthera.2011.06.005 ◽

2011 ◽

Vol 33 (7) ◽

pp. 973-989 ◽

Cited By ~ 30

Author(s):

Yoshiharu Horie ◽

Shigeto Kanada ◽

Hirotaka Watada ◽

Akiko Sarashina ◽

Atsushi Taniguchi ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Double Blind ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes

Drugs in R&D ◽

10.1007/s40268-015-0096-6 ◽

2015 ◽

Vol 15 (3) ◽

pp. 245-251 ◽

Cited By ~ 7

Author(s):

Rika Ito ◽

Tomoyasu Fukui ◽

Toshiyuki Hayashi ◽

Anna Osamura ◽

Makoto Ohara ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Secretion ◽

Early Phase ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Drug Naïve

Randomized Multicenter Evaluation of Quality of Life and Treatment Satisfaction in Type 2 Diabetes Patients Receiving Once-Weekly Trelagliptin Versus a Daily Dipeptidyl Peptidase-4 Inhibitor

Diabetes Therapy ◽

10.1007/s13300-019-0643-1 ◽

2019 ◽

Vol 10 (4) ◽

pp. 1369-1380 ◽

Cited By ~ 1

Author(s):

Hitoshi Ishii ◽

Yuki Suzaki ◽

Yuko Miyata ◽

Shingo Matsui

Keyword(s):

Quality Of Life ◽

Type 2 Diabetes ◽

Treatment Satisfaction ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Treatment progression in sulfonylurea and dipeptidyl peptidase-4-inhibitor cohorts of type 2 diabetes patients on metformin

Patient Preference and Adherence ◽

10.2147/ppa.s109664 ◽

2016 ◽

Vol Volume 10 ◽

pp. 1539-1546

Author(s):

Xiaomei Peng ◽

Dingfeng Jiang ◽

Dongju Liu ◽

Oralee Varnado ◽

Jay Bae

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Urinary exosomal microRNA profiling in type 2 diabetes patients taking dipeptidyl peptidase-4 inhibitor compared with sulfonylurea

Kidney Research and Clinical Practice ◽

10.23876/j.krcp.21.015 ◽

2021 ◽

Author(s):

Nam-Jun Cho ◽

Dae-Yeon Kim ◽

Soon Hyo Kwon ◽

Tae Won Ha ◽

Hyun Kyu Kim ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Microrna Profiling ◽

Exosomal Microrna ◽

Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand

ClinicoEconomics and Outcomes Research ◽

10.2147/ceor.s113559 ◽

2016 ◽

Vol Volume 8 ◽

pp. 521-529 ◽

Cited By ~ 4

Author(s):

Unchalee Permsuwan ◽

Piyameth Dilokthornsakul ◽

Surasak Saokaew ◽

Kednapa Thavorn ◽

Nathorn Chaiyakunapruk

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients

Diabetes Obesity and Metabolism ◽

10.1111/j.1463-1326.2009.01046.x ◽

2009 ◽

Vol 11 (8) ◽

pp. 786-794 ◽

Cited By ~ 128

Author(s):

T. Heise ◽

E. U. Graefe-Mody ◽

S. Hüttner ◽

A. Ring ◽

D. Trommeshauser ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Male Type ◽

Oral Doses ◽